trimipramine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
substances of the imipramine group 2758 739-71-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • trimipramine
  • rhotrimine
  • trimeprimine
  • trimeproprimine
  • trimipramine maleate
  • surmontil
  • trimipramine maleate salt
  • trimipramine mesylate
  • trimipramine monohydrochloride
Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.
  • Molecular weight: 294.44
  • Formula: C20H26N2
  • CLOGP: 5.44
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -4.05
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.15 g O
0.15 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 11.31 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 40 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 16 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 23 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 12, 1979 FDA ODYSSEY PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Traumatic coma 77.75 26.59 11 2417 61 50602635
Deafness transitory 57.39 26.59 14 2414 1782 50600914
Toxicity to various agents 53.50 26.59 58 2370 212441 50390255
Suicide attempt 49.92 26.59 31 2397 51701 50550995
Coma 49.68 26.59 32 2396 56847 50545849
Functional gastrointestinal disorder 48.36 26.59 14 2414 3428 50599268
Atrial septal defect 43.82 26.59 15 2413 6326 50596370
Parachute mitral valve 43.74 26.59 7 2421 97 50602599
Abnormal loss of weight 43.04 26.59 14 2414 5050 50597646
Coarctation of the aorta 37.43 26.59 8 2420 565 50602131
Product prescribing error 34.99 26.59 18 2410 20943 50581753
Patent ductus arteriosus 34.25 26.59 11 2417 3809 50598887
Polyglandular autoimmune syndrome type II 33.22 26.59 5 2423 45 50602651
Gastrointestinal pain 33.12 26.59 13 2415 8043 50594653
Feeding disorder 32.94 26.59 14 2414 10599 50592097
Miosis 32.49 26.59 12 2416 6298 50596398
Victim of sexual abuse 32.48 26.59 7 2421 514 50602182
Drug abuse 29.92 26.59 24 2404 59822 50542874
Ventricular septal defect 29.64 26.59 10 2418 4031 50598665
Prescription drug used without a prescription 28.78 26.59 8 2420 1692 50601004
Incorrect dosage administered 28.72 26.59 8 2420 1706 50600990
Drug interaction 28.40 26.59 41 2387 199580 50403116
Cancer fatigue 27.22 26.59 4 2424 30 50602666

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prescription drug used without a prescription 118.04 34.76 23 1124 1281 29572099
Brain oedema 74.88 34.76 25 1122 12195 29561185
Drug interaction 74.53 34.76 61 1086 197324 29376056
Toxicity to various agents 61.93 34.76 52 1095 173609 29399771
Pulmonary oedema 47.49 34.76 26 1121 42709 29530671

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prescription drug used without a prescription 136.55 24.29 30 2885 2570 64493247
Toxicity to various agents 107.56 24.29 105 2810 363408 64132409
Drug interaction 98.59 24.29 100 2815 361983 64133834
Traumatic coma 72.15 24.29 10 2905 50 64495767
Brain oedema 66.49 24.29 28 2887 22047 64473770
Coma 66.19 24.29 44 2871 87571 64408246
Suicide attempt 42.65 24.29 31 2884 70976 64424841
Miosis 37.19 24.29 16 2899 13250 64482567
Victim of sexual abuse 34.62 24.29 7 2908 400 64495417
Drug abuse 32.96 24.29 35 2880 132339 64363478
Somnolence 29.63 24.29 41 2874 203604 64292213
Pulmonary oedema 27.39 24.29 25 2890 78649 64417168
Product prescribing error 27.28 24.29 18 2897 35251 64460566
Incorrect dosage administered 27.12 24.29 8 2907 2218 64493599
Abdominal pain lower 26.73 24.29 16 2899 26453 64469364
Pneumonia aspiration 24.98 24.29 21 2894 59250 64436567
Aspiration 24.65 24.29 13 2902 16872 64478945
Eyelid bleeding 24.52 24.29 4 2911 67 64495750

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AA06 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Non-selective monoamine reuptake inhibitors
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:78298 environmental contaminants
MeSH PA D018663 Adrenergic Agents
MeSH PA D018759 Adrenergic Uptake Inhibitors
MeSH PA D000928 Antidepressive Agents
MeSH PA D000929 Antidepressive Agents, Tricyclic
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
FDA EPC N0000175752 Tricyclic Antidepressant

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Depressive disorder indication 35489007
Neuralgia off-label use 16269008
Ocular hypertension contraindication 4210003 DOID:9282
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Bipolar disorder contraindication 13746004 DOID:3312
Electroconvulsive therapy contraindication 23835007
Hyperthyroidism contraindication 34486009 DOID:7998
Conduction disorder of the heart contraindication 44808001
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Schizophrenia contraindication 58214004 DOID:5419
Epilepsy contraindication 84757009 DOID:1826
Kidney disease contraindication 90708001 DOID:557
Cerebrovascular accident contraindication 230690007
Mania contraindication 231494001
Hypomania contraindication 231496004
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Angle-closure glaucoma contraindication 392291006 DOID:13550
Disorder of coronary artery contraindication 414024009
Myocardial infarction in recovery phase contraindication 418044006




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.92 Basic
pKa2 5.01 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 6.83 PDSP IUPHAR
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 5.61 IUPHAR CHEMBL
Sodium-dependent dopamine transporter Transporter INHIBITOR Ki 5.42 PDSP IUPHAR
Histamine H1 receptor GPCR ANTAGONIST Ki 8.85 PDSP
Solute carrier family 22 member 1 Transporter IC50 4.56 CHEMBL

External reference:

IDSource
4019962 VUID
N0000148047 NUI
D00394 KEGG_DRUG
521-78-8 SECONDARY_CAS_RN
4018060 VANDF
4019962 VANDF
C0041056 UMLSCUI
CHEBI:9738 CHEBI
CHEMBL644 ChEMBL_ID
DB00726 DRUGBANK_ID
CHEMBL1200948 ChEMBL_ID
D014299 MESH_DESCRIPTOR_UI
5584 PUBCHEM_CID
7317 IUPHAR_LIGAND_ID
1414 INN_ID
25332-13-2 SECONDARY_CAS_RN
6S082C9NDT UNII
10834 RXNORM
2164 MMSL
5636 MMSL
72541 MMSL
d00873 MMSL
001507 NDDF
004605 NDDF
005363 NDDF
373550009 SNOMEDCT_US
734496007 SNOMEDCT_US
87831009 SNOMEDCT_US
90426002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 42806-802 CAPSULE 25 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 42806-803 CAPSULE 50 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 42806-804 CAPSULE 100 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 51991-944 CAPSULE 25 mg ORAL ANDA 23 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 51991-945 CAPSULE 50 mg ORAL ANDA 23 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 51991-946 CAPSULE 100 mg ORAL ANDA 23 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 68462-804 CAPSULE 25 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 68462-805 CAPSULE 50 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 68462-806 CAPSULE 100 mg ORAL ANDA 22 sections